item management s discussion and analysis of financial condition and results of operations 
overview since commencing operations in  the company has been a development stage company 
the company is engaged in research  development and commercialization of the adcon family of products  which are proprietary  resorbable  carbohydrate polymer medical devices designed to inhibit surgical scarring and adhesions 
based on european pivotal clinical studies and other compliance efforts and submission of data  the company obtained regulatory clearance to affix ce marking on adcon l and adcon t n in august and january  respectively  thereby allowing adcon l and adcon t n to be marketed in the european union countries which recognize ce marking for lumbar disc surgery and tendon and peripheral nerve surgeries  respectively 
the company is currently marketing adcon l and adcon t n through independent medical device distributors in countries outside the us  including the major countries in the european union pursuant to its ce marking 
in addition  the company signed a development and exclusive license agreement in december with chugai for the sale of adcon l and adcon t n in japan 
further  the company is pursuing the development of small molecule drug candidates for the treatment of several nervous system disorders  including adhd  sleep disorders  anxiety and ad 
in october  the company entered into a strategic alliance with janssen to collaborate on the discovery and development of therapeutic models to treat ad 
in september  the scope of the alliance was expanded and the current arrangement extends through october since inception  the company s revenues have been derived primarily from contract research payments relating to its strategic alliance with janssen 
the company has also received revenues from product sales of adcon l and adcon t n as well as from various government grants awarded to the company 
the company anticipates that a significant portion of revenue from product sales will be derived from its adcon family of products  primarily adcon l 
the company is a development stage company that has not generated any material revenues from operations 
as a result  the company has had net operating losses since its inception and expects such losses to continue unless and until such time as revenues are sufficient to fund its current operations 
the company has accumulated a deficit of million for the period from inception of operations august  through december  the company expects to continue to incur a loss over at least the next several years and the amount of future net losses and time required by the company to reach profitability are uncertain 
results of operations years ended december  and revenues 
total revenues increased approximately to million in from million in the increase in total revenues is primarily a result of a increase in product sales to million in from  in this increase in product sales primarily resulted from increased sales of the company s adcon l and adcon t n products in certain european countries  as well as other countries outside the us in addition  research contract revenues increased slightly to million in from million in these research contract revenues were from the company s research contract with janssen 
the company s government funded grant revenues increased to  in from  in this increase was the result of a higher level of government funded revenues primarily due to the award in february of a phase ii small business innovation research sbir program two year grant from the national institute of neurological disorders and stroke ninds for research to evaluate the histamine h receptor antagonists to treat adhd 
in addition  in the fourth quarter of  the company was awarded two  phase i sbir program grants i from ninds for research to evaluate the molecular characterization of the histamine receptor subtype and ii from the national institute of nursing research ninr for research to evaluate the inhibition of postoperative gynecological adhesions 
operating costs and expenses 
total operating expenses increased by approximately  to million in compared to million in cost of products sold increased to  in compared to  in and increased as a percentage of product sales in to from in this increase was primarily due to slightly increased manufacturing overhead costs which were added in anticipation of larger planned production volumes which were not obtained in research and development expenses increased by approximately to million in from million in this increase was primarily due to i increased research contract expenses and purchases of materials for preclinical and animal toxicology studies for the lead compound which is being developed by the company for the treatment of adhd  ii increased staffing and clinical consulting costs associated with the premarket approval application filed with the fda for adcon l  iii increased costs associated with the development of a new delivery system for adcon l and iv increased staffing and clinical research costs associated with preclinical and clinical development of adcon p 
selling  general and administrative expenses increased to million in  compared to million in the increase was primarily due to increases in expenses resulting from gliatech s sales and marketing efforts for adcon l and adcon t n in certain european markets and other selected countries outside of the us depreciation and amortization expense was  in compared to  in the increase was primarily due to increased amortization resulting from leasehold improvements made in and other income and expenses 
net interest income decreased to  in from million in this decrease was due to lower cash and cash equivalents and short term investment balances throughout as compared to in the fourth quarter of  the company incurred a one time non cash charge of million relating to the company s settlement of a claim involving the company 
see item legal proceedings and note k to the notes to consolidated financial statements included herein 
net loss 
gliatech s net loss increased to million in  compared to million in the net loss  excluding a one time non cash charge of million for settlement of the litigation  increased to million in from million in the increase in net loss is a result of increased total expenses  which were slightly offset by increased revenues as discussed above 
the net loss per share was in  compared to in and  excluding the one time non cash charge for settlement of the litigation  in  compared to in years ended december  and revenues 
total revenues increased approximately to million in from million in the increase in total revenues is primarily an increase in product sales to  in from  in the increase in product sales in resulted from sales of the company s adcon l and adcon t n products in certain european countries  as well as australia and new zealand 
the company had research contract revenues in of million from its research contract with janssen compared to research revenues of million in in september  the company entered into an addendum to the janssen agreement in order to expand the scope of the collaboration with janssen on ad to include research and development relating to inhibitors of complement activation 
this addendum to the janssen agreement added approximately  to research contract revenues in and  to research contract revenues in under the terms of the expanded agreement  janssen increased its research funding and milestone payments by beginning in september the company s government funded research grant revenues were  in and  in the level of grant revenues was a direct result of the number of government funded research grants awarded the company in each year 
operating costs and expenses 
total operating expenses were million in compared to million in cost of products sold increased to  in from  in the increase in cost of products sold was due primarily to the increases in product sales for the corresponding period 
however  cost of products sold decreased as a percentage of product sales in to from in this decrease was primarily due to improved absorption of manufacturing overhead costs as a result of increased production volumes in in both periods  cost of products sold included costs associated with the start up of manufacturing processes with european medical contract manufacturing emcm  a third party manufacturer of adcon l and adcon t n 
expenses for research and development increased to million in from million in this increase was due primarily to increased staffing and clinical contract expenses resulting from the initiation of pivotal clinical trials in the us for both adcon l and adcon t n beginning in the fourth quarter of and continuing throughout additionally  the increase is a result of additions in staffing and purchases of laboratory supplies and services relating to increased research activities beginning in the first quarter of with respect to ad and cognition modulation programs as well as write offs of costs associated with patents which were abandoned due to changes in the technology pursuits of the company 
increased expenses associated with the company s ad program are funded under the company s research agreement with janssen 
selling  general and administrative expenses increased to million in from million in this increase was primarily due to an increase in sales and marketing expenses as the company continued to expand its sales and marketing efforts for its adcon l and adcon t n products in europe and in other countries outside the us additionally  the company incurred increased general and administrative expenses of  in associated with the filing of a registration statement with the us securities and exchange commission for an offering of common stock which was subsequently withdrawn due to unfavorable market conditions 
the company also incurred increased general and administrative expenses in associated with its first full year of reporting as a publicly traded company 
depreciation and amortization expense was  in compared to  in this expense decreased because several company assets had become fully depreciated 
other income and expenses 
net interest income increased to million in from  in the increase in was due primarily to the interest earned on the cash received on the october initial public offering of common stock 
in addition  interest expense decreased in both periods as the company paid down its line of credit and fully repaid its capital leases 
net loss 
the company s net loss increased to million in  compared to million in the increase in net loss is a result of increased total expenses  which were slightly offset by increased revenues as discussed above 
the net loss per share was in  compared to in liquidity and capital resources since inception  the company has financed its operations primarily through the private placement and public offering of its equity securities  research contract licensing fees  and  to a lesser extent  through federally sponsored research grants 
since its inception  the company has received million in net proceeds from equity financings 
in addition  from its inception through december   the company has recognized revenue of million from its research agreement with janssen  million from product sales and million from several federally sponsored research grants 
the company has also established a million line of credit with a bank  secured by certain assets of the company 
as of december   the company had no borrowings against the line of credit 
in order to preserve principal and maintain liquidity  the company s funds are invested in commercial paper and other short term investments 
as of december  and december   the company s cash and cash equivalents and short term investments totaled million and million  respectively 
the company expects that its existing capital resources  and interest earned thereon  will enable the company to maintain its current and planned operations at least through mid the company may need to raise substantial additional capital to fund its operations prior to such time 
the company s future capital requirements will depend on  and could increase as a result of many factors  including  but not limited to  the costs for commercialization of adcon l  the commercial success of its adcon family of products  the progress of the company s research and development  including the costs related to its cognition modulation and ad programs  the scope  timing and results of preclinical studies and clinical trials  the cost and timing of obtaining regulatory approvals  its success in obtaining the strategic alliances required to fund certain of its programs  the rate of technological advances  determinations as to the commercial potential of certain of the company s product candidates  the status of competitive products and the establishment of additional manufacturing capacity 
in and  the company received revenues from two phase i sbir grants for up to  each from the ninds division of the national institute of health relating to the development of histamine h receptor agents 
in february  the company was awarded a phase ii sbir program grant from the ninds for research evaluating histamine h receptor antagonists to treat adhd 
the grant has a two year term and may provide as much as  in funding 
if the company is successful in other phase i research  additional phase ii awards may be sought for funding to aid in further development of pharmaceutical compounds  however  there is no assurance that such phase i research will be successful or that additional funding will be obtained 
in addition  in the fourth quarter of  the company was awarded two phase i sbir grants for up to  each from the ninds and the ninr divisions of the national institute of health 
the company does not expect to generate a positive cash flow from operations for several years due to the substantial costs for commercialization of its adcon family of products  additional research and development costs for adcon a  adcon i and adcon c and for costs related to its cognition modulation and ad programs  preclinical testing  clinical trials and operating expenses associated with supporting such activities 
the company may raise additional funds through additional equity or debt financing  government grants  further corporate alliances  collaborative relationships  or otherwise 
the company may engage in these capital raising activities even if it does not have an immediate need for additional capital at that time 
there can be no assurance that any such additional funding will be available to the company or  if available  that it will be on acceptable terms 
if additional funds are raised by issuing equity securities  further dilution to existing shareholders may result 
if adequate funds are not available  the company may be required to delay  reduce the scope of  or eliminate one or more of its research  development or clinical trials 
if the company seeks to obtain funds through arrangements with collaborative partners or others  such partners may require the company to relinquish rights to certain of its technologies  product candidates or products that the company would otherwise seek to develop or commercialize itself 
net operating loss carryforwards 
as of december   the company has available for federal income tax purposes net operating loss carryforwards of approximately million and research and development credit carryforwards of approximately million 
these carryforwards expire at various dates between and the company has offset the tax benefit of the net operating loss and tax credit carryforwards with a valuation allowance as realization of the benefit is not assured 
pursuant to the tax reform act of  the utilization of net operating loss and research and development tax credit carryforwards for tax purposes may be subject to an annual limitation if a cumulative change in ownership of more than occurs over a three year period 
the future issuance of securities by the company and or sales of securities by the company s principal stockholders could result in such a change in ownership 
see note f of notes to consolidated financial statements included herein 
year the company has conducted a review of its information systems to identify any issues that could be affected by the year although the company believes that its information systems are able to process year and date information beyond the year  the company is unable to determine the extent to which year issues will affect its independent distributors or emcm in tracking sales  orders or shipments of the company s devices or drugs  as the case may be 
any interruption in the manufacturing or marketing of the company s products could have a material adverse effect on the company s business  prospects  financial condition or results of operations 
forward looking statements 
certain statements in this annual report on form k constitute forward looking statements 
when used in this report  the words believes  anticipates  expects  intends and other predictive  interpretive and similar expressions are intended to identify such forward looking statements 
such forward looking statements involve known and unknown risks  uncertainties and other factors which may cause the actual results of the company to be different from expectations expressed or implied by such forward looking statements 
such factors include  but are not limited to  the uncertainty of final regulatory approvals of the pma application for adcon l  including the timing and content of decisions made by the fda  commercial uncertainty of market acceptance of the company s adcon family of products  delays in product development of other adcon products  uncertainty due to the early stage of development for the therapeutic programs  the possible need for additional funding  the ability of the company to establish and maintain collaborative arrangements with others  the potential market size for adcon products  the ability to renew research collaborations  the productivity of distributors of the adcon products  shortages of supply of adcon products from the company s sole manufacturer  the lack of supply of raw materials for the company s products  uncertainty of future profitability  uncertainties related to the company s proprietary rights in its products  the loss of key management personnel  and technological change 
these statements are based on certain assumptions and analysis made by the company in light of its experience and its perception of historical trends  current conditions  expected future developments and other factors it believes are appropriate in the circumstances 
such statements are subject to a number of other assumptions  risks  uncertainties  general economic and business conditions  and the business opportunities or lack thereof that may be presented to and pursued by the company 
prospective investors are cautioned that any such statements are not guaranteed of future performance and that actual results or developments may differ materially from those projected in the forward looking statements 
the accompanying information contained in this annual report on form k  including  without limitation  the information set forth in this section and under item business  identifies important factors that could cause such differences 
item a 
quantitative and qualitative disclosures about market risk not applicable 

